Skip to main content

Research Repository

Advanced Search

All Outputs (5)

Recurrent ACVR1 mutations in posterior fossa ependymoma (2022)
Journal Article
Pratt, D., Lucas, C.-H. G., Selvam, P. P., Abdullaev, Z., Ketchum, C., Quezado, M., Armstrong, T. S., Gilbert, M. R., Papanicolau-Sengos, A., Raffeld, M., Choo-Wosoba, H., Chan, P., Whipple, N., Nasrallah, M., Santi, M., Ramaswamy, V., Giannini, C., Ritzmann, T. A., Grundy, R. G., Burford, A., …Aldape, K. (2022). Recurrent ACVR1 mutations in posterior fossa ependymoma. Acta Neuropathologica, 144, 373-376. https://doi.org/10.1007/s00401-022-02435-2

MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial (2022)
Journal Article
Rodriguez, D., Calmon, R., Aliaga, E. S., Warren, D., Warmuth-Metz, M., Jones, C., Mackay, A., Varlet, P., Le Deley, M. C., Hargrave, D., Cañete, A., Massimino, M., Azizi, A. A., Saran, F., Zahlmann, G., Garcia, J., Vassal, G., Grill, J., Peet, A., Dineen, R. A., …Jaspan, T. (2022). MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial. Radiology, 304(1), 174-182. https://doi.org/10.1148/radiol.211464

Background Diffuse midline gliomas (DMG) are characterized by a high incidence of H3 K27 mutations and poorer outcome. The HERBY trial has provided one of the largest cohorts of pediatric DMGs with available radiologic, histologic-genotypic, and surv... Read More about MRI and Molecular Characterization of Pediatric High-Grade Midline Thalamic Gliomas: The HERBY Phase II Trial.

Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma (2018)
Journal Article
Grill, J., Massimino, M., Bouffet, E., Azizi, A. A., McCowage, G., Cañete, A., Saran, F., Le Deley, M.-C., Varlet, P., Morgan, P. S., Jaspan, T., Jones, C., & Giangaspero, F. (2018). Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma. Journal of Clinical Oncology, 36(10), https://doi.org/10.1200/JCO.2017.76.0611

Purpose
Bevacizumab (BEV) is approved in more than 60 countries for use in adults with recurrent glioblastoma. We evaluated the addition of BEV to radiotherapy plus temozolomide (RT+TMZ) in pediatric patients with newly diagnosed high-grade glioma (... Read More about Phase II, open-label, randomized, multicenter trial (HERBY) of Bevacizumab in pediatric patients with newly diagnosed high-grade glioma.

Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours (2017)
Journal Article
Haque, F., Varlet, P., Puntonet, J., Storer, L., Bountali, A., Rahman, R., Grill, J., Carcaboso, A. M., Jones, C., Layfield, R., & Grundy, R. G. (2017). Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours. Acta Neuropathologica Communications, 5, 1-9. https://doi.org/10.1186/s40478-017-0449-1

Missense somatic mutations affecting histone H3.1 and H3.3 proteins are now accepted as the hallmark of paediatric diffuse intrinsic pontine gliomas (DIPG), non-brain stem paediatric high grade gliomas (pHGG) as well as a subset of adult glioblastoma... Read More about Evaluation of a novel antibody to define histone 3.3 G34R mutant brain tumours.